Health Sovereignty on the Agenda: The Fiscal and Exchange Rate Cost of Protectionism

Deepening the reading from the perspective of the tradition of value and margin of safety, the investor should not confuse national autonomy speeches with a guarantee of corporate financial return, as companies in the pharmaceutical and health sectors often operate with high debt to finance the capex of local industrial plants. This is the sixth adversely toned news published by our portal in the economic policy section this week, reflecting a complex regulatory ecosystem where frequent state interference alters the risk profile of listed companies. The absence of comfortable operating margins, combined with exchange rate volatility, requires the shareholder to have redoubled tactical patience before allocating capital to theses focused exclusively on the regulated domestic market.

Technically, the structural causes of this health and economic vulnerability date back to decades of disinvestment in basic research and development, resulting in an industrial park incapable of absorbing global supply shocks without compromising the Union's fiscal budget. The fiscal risks arising from eventual tax exemptions or cross-subsidies to stimulate domestic production of vaccines and drugs collide frontally with the need for austerity demanded by the current Selic target rate at 14% per year. With basic interest rates stagnated at high levels both in the 7-day reading and in the 30-day horizon, the opportunity cost of corporate capital rises drastically, making factory expansion projects that depend exclusively on traditional bank financing unviable.

For the next 30 days, share price volatility is projected in the equities of companies linked to the health subsector and hospital distribution, pressured by the volatile exchange rate and the rising cost of corporate credit. Over the 90-day horizon, the market is expected to price in the initial budgetary impacts.